DOCTOR AND SCIENTIST, DR. CLIFFORD STEER, JOINS THE LUCIOLE PHARMACEUTICALS SCIENTIFIC ADVISORY ADVISORY BOARD

Firefly Pharmaceuticals

Dr. Clifford Stear

Dr. Steer’s research has focused on liver regeneration and neurodegenerative disorders, including Huntington’s disease, ALS, and Parkinson’s disease.

The most important subcellular organelle is NOT the nucleus, but rather the mitochondria. Without them and their intact mtDNA content, the cell undergoes apoptosis and dies.

– Clifford Stear, MD.

NATIC, Massachusetts, USA, June 21, 2022 /EINPresswire.com/ – DOCTOR AND SCIENTIST, CLIFFORD STEAR, MD, JOINS THE LUCIOLE PHARMACEUTICALS SCIENTIFIC ADVISORY BOARD

Natick, Massachusetts – June 21, 2022 – Luciole Pharmaceuticals, Inc. is pleased to announce that Clifford Stear, MD, is joining the company’s scientific advisory board.
Dr. Steyr is Professor of Medicine and Genetics, Cell Biology and Development at the University of Minnesota School of Medicine, Minneapolis, Minnesota. He is a member of the Stem Cell Institute, the Masonic Cancer Center, the Institute of Medical Engineering and the Lillehey Heart Institute. His research spans more than four decades and focuses on
liver regeneration and neurodegenerative disorders, including Huntington’s disease, ALS and Parkinson’s disease.

His experience spans a wide variety of disciplines, including epigenetics, microRNA, receptor-mediated endocytosis, nonviral gene therapy, and gene editing, which has led to more than 300 scientific papers. He has organized and chaired many national and international scientific conferences related to liver disease and has been a longtime member of several sections of the National Institutes of Health Research, co-editor of a major scientific journal on liver disease (Hepatology), former editorial board member of Liver Transplantation and genetic vaccines and therapy and currently serves on the editorial board of Liver Medicine and Genes.

Dr. Steer was elected a Fellow of the American Society for Clinical Research in 1991, and in 2014 was elected the first Fellow of the American Association for the Study of Liver Disease.
“Unlike what I was taught in school when I was growing up, the most important subcellular organelle is NOT the nucleus, but rather the mitochondria. Without them and their intact mtDNA content, the cell undergoes apoptosis and dies. Critical to their death is ROS, which impairs the structure / function of mtDNA, “said Dr. Steer.” Luciole’s cutting-edge technology to repair this damage translates into cell survival and, more importantly, potential treatment for a wide variety of diseases. including neurodegenerative, cardiac and hepatic “
Dr. Steer’s research on mitochondrial stabilization and subsequent prevention of apoptosis, together with his experience in liver disease, provides an ideal combination of clinical and core research interests and experience in support of Luciole’s goals for developing new therapeutic agents targeting mitochondrial DNA in obesity, metabolic syndrome and fatty liver disease. We are very excited that he has joined us in our mission, “said Dennis I. Goldberg, PhD, President and CEO of Luciole Pharmaceuticals.

About Luciole Pharmaceuticals

Luciole Pharmaceuticals is a start-up biotechnology company that is developing new therapeutic agents to repair damaged mtDNA, a critical aspect of the aging process. Mitochondria provide all mammalian cells with energy that is essential for healthy tissues and longevity. A natural by-product of this function is the production of reactive oxygen species (ROS). The mitochondrial genome (mtDNA) is physically linked to the primary site of ROS generation. Oxidative damage to mtDNA is a relentless aspect of human aging, causing mitochondrial dysfunction, mtDNA breakdown, activation of the innate immune system – and ultimately cell death. Luciole is the first company to focus on improving the recovery of oxidatively damaged mtDNA.

Luciole’s technology, which aims to detect and develop small molecule agonists for OGG1 (8-oxoguanine DNA glycosylase), the key enzyme for initiating excision-based recovery (BER) of both nuclear and mtDNA, is based on cutting-edge work. of Dr. Ramsey, co-founder of Luciole, in collaboration with Vilhelm Bohr, MD, Ph.D., head of the Molecular Gerontology Laboratory at the National Institute on Aging, and co-founders, R. Stephen Lloyd and Amanda K. McCullough of the University of Health and Science in Oregon (OHSU). Luciole was established as a division of OHSU with an exclusive worldwide license to commercialize patented OGG1 small molecule activators based on Lloyd / McCullough compounds. For more information, visit www.luciolepharma.com.

Firefly Investor Contact:

Dennis Goldberg, Ph.D. [email protected]

Donald Day [email protected]

Dennis Goldberg
Firefly Pharmaceuticals
+ +1 5088787589
send us an email here
Visit us on social networks:
LinkedIn

Leave a Comment

Your email address will not be published.